Jefferies heads $1 billion fundraiser for COVID-19 packaging driveAs research efforts to find drugs effective against COVID-19 gather pace, a public-private partnership has been set up Share XJefferies heads $1 billion fundraiser for COVID-19 packaging drivehttps://pharmaphorum.com/news/jefferies-heads-1-billion-fundraiser-for-covid-19-packaging-drive/
How would single payer healthcare in the US impact pharma? A pricing perspectiveThe US healthcare system is the most complicated amongst advanced industrialised countries. Health care provision is made up Share XHow would single payer healthcare in the US impact pharma? A pricing perspectivehttps://pharmaphorum.com/views-analysis-market-access/how-would-single-payer-healthcare-in-the-us-impact-pharma-a-pricing-perspective/
ICER methods could be illegal in US, claims US think tankThe method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether drugs are Share XICER methods could be illegal in US, claims US think tankhttps://pharmaphorum.com/news/icer-methods-could-be-illegal-in-us-claims-us-think-tank/
5 years of biosimilars in the US: what have we learned?Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients Share X5 years of biosimilars in the US: what have we learned?https://pharmaphorum.com/views-analysis-market-access/5-years-of-biosimilars-in-the-us-what-have-we-learned/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Secret US-UK talks on drug pricing revealedDespite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at Share XSecret US-UK talks on drug pricing revealedhttps://pharmaphorum.com/views-analysis-market-access/secret-us-uk-talks-on-drug-pricing-revealed/
Measuring value to ensure access in divisive timesGlobally, balancing rising healthcare costs with the drive for innovation is a political hot potato – is a Share XMeasuring value to ensure access in divisive timeshttps://pharmaphorum.com/views-analysis-market-access/measuring-value-to-ensure-access-in-divisive-times/
California is first US state to ban pay-for-delay dealsCalifornia has become the first US state to ban the pharma industry practice of paying rivals to keep Share XCalifornia is first US state to ban pay-for-delay dealshttps://pharmaphorum.com/news/california-is-first-us-state-to-ban-pay-for-delay-deals/
Medicare coverage for CAR-T drugs on the horizonMedicare could soon cover CAR-T therapies under new proposals from the US’ Centers for Medicare & Medicaid Services Share XMedicare coverage for CAR-T drugs on the horizonhttps://pharmaphorum.com/news/medicare-coverage-for-car-t-drugs-on-the-horizon/
